[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356268-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356268-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","xelox-combined-with-sintilimab-and-hyperbaric-oxygen-therapy-for-advanced-or-metastatic-gastricgastroesophageal-junction-adenocarcinoma-study-protocol-for-a-prospective-single-arm-phase-ibii-clinical-trial","XELOX combined with sintilimab and hyperbaric oxygen therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma - study protocol for a prospective, single-arm, phase Ib/II clinical trial","","A prospective, single-center, single-arm phase Ib/II trial evaluates the efficacy and safety of the XELOX regimen combined with sintilimab and hyperbaric oxygen therapy (HBOT) in HER2-negative advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma. Phase Ib uses a 3+3 dose-escalation design in nine patients to establish safety and the optimal HBOT protocol. Phase II enrolls 48 patients, targeting objective response rate (ORR) as the primary endpoint and assessing PFS, DCR, 2-year DFS, 2-year OS, QoL, and safety.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/xelox-combined-with-sintilimab-and-hyperbaric-oxygen-therapy-for-advanced-or-metastatic-gastricgastroesophageal-junction-adenocarcinoma-study-protocol-for-a-prospective-single-arm-phase-ibii-clinical-trial/356268/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/xelox-combined-with-sintilimab-and-hyperbaric-oxygen-therapy-for-advanced-or-metastatic-gastricgastroesophageal-junction-adenocarcinoma-study-protocol-for-a-prospective-single-arm-phase-ibii-clinical-trial/356268.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of this study protocol?","Question",{"text":63,"@type":64},"To evaluate the efficacy and safety of XELOX plus sintilimab combined with HBOT for patients with HER2-negative advanced or metastatic gastric/GEJ adenocarcinoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are phases Ib and II designed in this trial?",{"text":68,"@type":64},"Phase Ib uses a 3+3 dose-escalation approach with nine patients to assess safety and determine the optimal HBOT protocol; Phase II enrolls 48 patients with ORR as the primary endpoint.",{"name":70,"@type":61,"acceptedAnswer":71},"What endpoints does the trial measure besides ORR?",{"text":72,"@type":64},"Secondary endpoints include progression-free survival (PFS), disease control rate (DCR), 2-year disease-free survival (DFS), 2-year overall survival (OS), quality of life (QoL), and safety.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356268,1790192491,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","TYPE Study Protocol  \nPUBLISHED 12 January 2026  \nDOI 10.3389/fimmu.2025.1672725  \nOPEN ACCESS  \nEDITED BY  \nStavros P. Papadakos,  \nLaiko General Hospital of Athens, Greece  \nREVIEWED BY  \nStamatios E Theocharis,  \nNational and Kapodistrian University of Athens, Greece  \nIoannis Katsaros,  \nNational and Kapodistrian University of Athens, Greece  \n*CORRESPONDENCE  \nMing Liu  \n [liuming629@wchscu.cn](liuming629@wchscu.cn)[ ](liuming629@wchscu.cn)Cheng Huang  \n [chenghuang_scu@163.com](chenghuang_scu@163.com)[ ](chenghuang_scu@163.com)Lin Zhu  \n [13880262860@163.com](13880262860@163.com)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 24 July 2025  \nREVISED 12 October 2025  \nACCEPTED 16 December 2025  \nPUBLISHED 12 January 2026  \nCITATION  \nLi W, Zhang P, Cheng M, Wei J, Xu M, Li D, Song S, Liu M, Huang C and Zhu L (2026) XELOX combined with sintilimab and hyperbaric oxygen therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase Ib/II clinical trial.  \nFront. Immunol. 16:1672725 .  \ndoi: 10.3389/fimmu.2025.1672725  \nCOPYRIGHT  \n© 2026 Li, Zhang, Cheng, Wei, Xu, Li, Song, Liu, Huang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nXELOX combined with sintilimab and hyperbaric oxygen therapy for advanced or metastatic gastric/ gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase Ib/II clinical trial  \nWenke Li 1†, Pengfei Zhang 1†, Mo Cheng 1, Jing Wei 1, Menghui Xu 1, Dan Li 2, Sihui Song 2, Ming Liu 1*, Cheng Huang 2* and Lin Zhu 3*  \n1Gastric Cancer Center/Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China, 2 Department of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, 3 Department of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China  \nBackground: Gastric and gastroesophageal junction cancer (GC/GEJC) is the ﬁfth most common and deadliest cancers worldwide, with ﬁve-year survival rates ranging from 20–40% due to late-stage diagnosis. First-line treatment for HER2-negative advanced or metastatic GC/GEJC involves chemotherapy combined with PD-1 inhibitors, achieving an objective response rate (ORR) of approximately 60% . However, primary and acquired resistance limits effectiveness, highlighting the need for novel strategies. Tumor hypoxia reduces the efﬁcacy of immune checkpoint inhibitors (ICIs) . Hyperbaric oxygen therapy (HBOT) may alleviate hypoxia, enhance drug delivery, and improve immune cell inﬁltration, potentially increasing the antitumor effects of ICIs.  \nMethods: This prospective, single-center, single-arm phase Ib/II trial evaluated the efﬁcacy and safety of the XELOX regimen combined with sintilimab and HBOT in HER2-negative advanced or metastatic GC/GEJC patients. Phase Ib employs a 3 + 3 dose-escalation design with nine patients to assess safety and determine the optimal HBOT protocol. Phase II will enrol 48 patients, accounting for a 5% dropout rate, with a focus on the ORR as the primary endpoint. The secondary endpoints include progression-free survival (PFS), the disease control rate (DCR), 2-year disease free survival (DFS), two-year overall survival (OS), quality of life (QoL), and safety. All participants received XELOX, sintilimab and HBOT. Efﬁcacy is assessed every two cycles, with maintenance therapy continuing until disease progression or other termination criteria are met.  \nFrontiers in Immunology 01 [frontiers","cbCaihKGyFJZNo9N","https://ap.wps.com/l/cbCaihKGyFJZNo9N","pdf",2764231,11,"English","# Introduction\n# Background\n# Methods\n# Discussion\n# Trial registration details\n# Trial endpoints and schedule","[{\"question\":\"What is the main purpose of this study protocol?\",\"answer\":\"To evaluate the efficacy and safety of XELOX plus sintilimab combined with HBOT for patients with HER2-negative advanced or metastatic gastric/GEJ adenocarcinoma.\"},{\"question\":\"How are phases Ib and II designed in this trial?\",\"answer\":\"Phase Ib uses a 3+3 dose-escalation approach with nine patients to assess safety and determine the optimal HBOT protocol; Phase II enrolls 48 patients with ORR as the primary endpoint.\"},{\"question\":\"What endpoints does the trial measure besides ORR?\",\"answer\":\"Secondary endpoints include progression-free survival (PFS), disease control rate (DCR), 2-year disease-free survival (DFS), 2-year overall survival (OS), quality of life (QoL), and safety.\"}]","XELOX combined with sintilimab and hyperbaric oxygen therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma - study protocol for a prospective, single-arm, phase Ib/II clinical trial | PDF",1790124357,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddf598e6a7e0d0240f008e22c73b49a1.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66d5f8494fb6d666a0d8595e3aec99df.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/727c7e6c6831b85676a386d399b3ffef.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e36dc13b2bb28f39ab84d47f64df2fd.webp",980,1385]